A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: No pharmacologic therapy has conclusively proved to be effective for the treatment of nonalcoholic steatohepatitis, which is characterized by insulin resistance, steatosis, and necroinflammation with or without centrilobular fibrosis. Pioglitazone is a thiazolidinedione that ameliorates insulin resistance and improves glucose and lipid metabolism in type 2 diabetes mellitus. METHODS: We randomly assigned 55 patients with impaired glucose tolerance or type 2 diabetes and liver biopsy-confirmed nonalcoholic steatohepatitis to 6 months of treatment with a hypocaloric diet (a reduction of 500 kcal per day in relation to the calculated daily intake required to maintain body weight) plus pioglitazone (45 mg daily) or a hypocaloric diet plus placebo. Before and after treatment, we assessed hepatic histologic features, hepatic fat content by means of magnetic resonance spectroscopy, and glucose turnover during an oral glucose tolerance test ([14C]glucose given with the oral glucose load and [3H]glucose given by intravenous infusion). RESULTS: Diet plus pioglitazone, as compared with diet plus placebo, improved glycemic control and glucose tolerance (P<0.001), normalized liver aminotransferase levels as it decreased plasma aspartate aminotransferase levels (by 40% vs. 21%, P=0.04), decreased alanine aminotransferase levels (by 58% vs. 34%, P<0.001), decreased hepatic fat content (by 54% vs. 0%, P<0.001), and increased hepatic insulin sensitivity (by 48% vs. 14%, P=0.008). Administration of pioglitazone, as compared with placebo, was associated with improvement in histologic findings with regard to steatosis (P=0.003), ballooning necrosis (P=0.02), and inflammation (P=0.008). Subjects in the pioglitazone group had a greater reduction in necroinflammation (85% vs. 38%, P=0.001), but the reduction in fibrosis did not differ significantly from that in the placebo group (P=0.08). Fatigue and mild lower-extremity edema developed in one subject who received pioglitazone; no other adverse events were observed. CONCLUSIONS: In this proof-of-concept study, the administration of pioglitazone led to metabolic and histologic improvement in subjects with nonalcoholic steatohepatitis. Larger controlled trials of longer duration are warranted to assess the long-term clinical benefit of pioglitazone. (ClinicalTrials.gov number, NCT00227110 [ClinicalTrials.gov] .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Significant improvements were observed in hepatic steatosis, hepatocellular ballooning, necrosis, and inflammation; however, fibrosis reduction did not reach statistical significance compared with placebo.”
From Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages (2026) · cites this paper as [202]
In the citing paper
“Accruing randomized clinical trial data suggest that pioglitazone, GLP-1 RA, and a dual GIP and GLP-1 RA have potential benefits in terms of decreasing hepatic steatosis and in the resolution of MASH without worsening of fibrosis in individuals with biopsy-proven MASH or those at higher risk of clinically significant liver fibrosis identified with noninvasive tests (146-153).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [146]
In the citing paper
“Treatment with exenatide reduced liver steatosis [109,146,150] and when added to pioglitazone, an oral hypoglycemic and insulin sensitizing drug approved for the treatment of T2D that acts on nuclear peroxisome proliferator activated receptor-gamma (PPAR-γ) [147], potentiated the known action of pioglitazone in reducing hepatic fat [92].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [92]
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621
Self-citationYamauchi, T., Kamon, J., Minokoshi, Y., Ito, Y., Waki, H., Uchida, S., Yamashita, S., Noda, M., Kita, S., Ueki, K., et al. (2002) · Nature Medicine · doi:10.1038/nm788 · Cited by 4,238
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease
Ratziu, V., Charlotte, F., Heurtier, A., Gombert, S., Giral, P., Bruckert, E., Grimaldi, A., Capron, F., & Poynard, T. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.084 · Cited by 2,106
Molecular mediators of hepatic steatosis and liver injury
Browning, J. D., & Horton, J. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422422 · Cited by 1,772
Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease
Samuel, V. T., Liu, Z.-X., Qu, X., Elder, B. D., Bilz, S., Befroy, D., Romanelli, A. J., & Shulman, G. I. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313478200 · Cited by 1,322
Xu, A., Wang, Y., Keshaw, H., Xu, L. Y., Lam, K. S. L., & Cooper, G. J. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317797 · Cited by 1,298
Xu, A., Wang, Y., Keshaw, H., Xu, L. Y., Lam, K. S. L., & Cooper, G. J. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17797 · Cited by 1,296
Research works printed but not linked: 3
- 10.1111/j.1572-0241.2003.08699.x · doi:10.1111/j.1572-0241.2003.08699.x · Paper page
- 10.1210/jc.87.6.2784 · doi:10.1210/jc.87.6.2784 · Paper page
- 10.1172/JCI22422 · DOI · Paper page
Cited by
Items 701–800 of 1,003
Bajaj, H. S., Brown, R. E., Bhullar, L., Sohi, N., Kalra, S., & Aronson, R. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.08.001 · Cited by 50
Management of diabetes mellitus in patients with cirrhosis: An overview and joint statement
Boursier, J., Anty, R., Carette, C., Cariou, B., Castéra, L., Caussy, C., Fontaine, H., Garioud, A., Gourdy, P., Guerci, B., et al. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2021.101272 · Cited by 55
“Among the randomised placebo-controlled trials performed on the evaluation of pioglitazone for the treatment of NASH, almost all patients included had no liver cirrhosis [63-67].”
BackgroundPioglitazone retrieves hepatic antioxidant DNA repair in a mice model of high fat diet
Hsiao, P., Hsieh, T., Kuo, K., Hung, W., Tsai, K., Yang, C.-H., Yu, M., & Shin, S. (2008) · BMC Molecular Biology · doi:10.1186/1471-2199-9-82 · Cited by 50
“This finding is consistent with the hepatic salvage effect of pioglitazone in the human studies reported by Belfort et al and Lutchman et al [17,28].”
Novel treatment modalities for nonalcoholic steatohepatitis
Satapathy, S. K., & Sanyal, A. J. (2010) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2010.08.003 · Cited by 52
Current and Emerging Therapies in Nonalcoholic Fatty Liver Disease
Kashi, M. R., Torres, D. M., & Harrison, S. A. (2008) · Seminars in Liver Disease · doi:10.1055/s-0028-1091984 · Cited by 53
Self-citationDoycheva, I., & Loomba, R. S. (2014) · Advances in Therapy · doi:10.1007/s12325-013-0084-6 · Cited by 53
Nonalcoholic fatty liver disease: Diagnosis, pathogenesis, and management
Basaranoglu, M., & Ormeci, N. (2014) · The Turkish Journal of Gastroenterology · doi:10.5152/tjg.2014.7675 · Cited by 48
“A meta-analysis of studies performed with thiazolidines showed improvements in steatosis, hepatocyte ballooning, and inflammation but not in fibrosis (49-55).”
Paediatric non‐alcoholic fatty liver disease: an overview
AlKhater, S. A. (2015) · Obesity Reviews · doi:10.1111/obr.12271 · Cited by 61
“Thiazolidinediones are another class of insulin sensitizers that were studied in adults and showed good results in improving the histological features of NASH (109).”
BackgroundThe role of apolipoprotein A5 in non-alcoholic fatty liver disease
Ress, C., Moschen, A. R., Sausgruber, N., Tschoner, A., Graziadei, I., Weiss, H., Schgoer, W., Ebenbichler, C. F., Konrad, R. J., Patsch, J. R., et al. (2011) · Gut · doi:10.1136/gut.2010.222224 · Cited by 56
Chew, N., Ng, C. H., Muthiah, M. D., & Sanyal, A. J. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01027-5 · Cited by 53
Gawrieh, S., Marion, M. C., KOMOROWSKI, R. A., Wallace, J. R., Charlton, M., Kissebah, A. H., Langefeld, C. D., & Olivier, M. (2011) · Digestive Diseases and Sciences · doi:10.1007/s10620-011-1994-2 · Cited by 50
“PPARG agonists have been used in therapeutic trials for NASH [23, 29, 35– 38].”
MethodLoomba, R., Wesley, R., Pucino, F., Liang, T. J., Kleiner, D. E., & Lavine, J. E. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.07.013 · Cited by 48
Farnesoid X Receptor: From Medicinal Chemistry To Clinical Applications
Fiorucci, S., Mencarelli, A., Distrutti, E., & Zampella, A. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.41 · Cited by 50
Dongiovanni, P., Rametta, R., Meroni, M., & Valenti, L. (2016) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2016.1110018 · Cited by 47
Veelen, A., Erazo‐Tapia, E., Oscarsson, J., & Schrauwen, P. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101158 · Cited by 53
Sohn, W., Lee, Y., Kim, S. S., Kim, J. H., Jin, Y., Kim, G., Sung, P. S., Yoo, J., Chang, Y. W., Lee, E. J., et al. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0045 · Cited by 76
Present and future therapeutic strategies in non-alcoholic fatty liver disease
Calamita, G., & Portincasa, P. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.9.1231 · Cited by 48
“3 Drugs improving insulin sensitivity Drugs capable of decreasing insulin resistance and increasing hepatic insulin sensitivity have been tested in NAFLD/NASH [113-116] , but there are few, rigorous controlled trials [86] testing the effect of biguanides (metformin) [117,118] and glitazones [119,120] on either ultra s…”
BackgroundMethodRecomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2
Torre, E. L. M., Tejedor, J. L., Menéndez, S. A., NúñezfiCortés, J. M., Garcia, A. A., Puig‐Domingo, M., Soláns, J. R. G., Guisasola, F. Á., Alegría, J. G., Bravo, J. J. M., et al. (2010) · Avances en Diabetología · doi:10.1016/s1134-3230(10)65006-5 · Cited by 64
Hwang, Y., Oh, D.-H., Choi, M. C., Lee, S. Y., Ahn, K. J., Chung, H.-Y., Lim, S., Chung, S. H., & Jeong, I. (2017) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2015.208 · Cited by 45
“Pentoxifilline [9], orlistat [10], ursodeoxycholic acid [11], metformin [12], and thiazolidinediones [13] have proved successful in humans.”
BackgroundCurrent and future treatment options in non-alcoholic steatohepatitis (NASH)
Lazaridis, N., & Tsochatzis, E. (2017) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2017.1293523 · Cited by 47
“alone in 55 patients with NASH, pioglitazone significantly improved all histological measures apart from fibrosis [68].”
BackgroundThe effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD)
Prat, L. I., & Tsochatzis, E. A. (2018) · HORMONES · doi:10.1007/s42000-018-0021-9 · Cited by 50
Mann, J. P., Tang, G. Y., Nobili, V., & Armstrong, M. J. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.05.023 · Cited by 52
Chan, W., Tan, S., Chan, S., Lee, Y., Tee, H., Mahadeva, S., Goh, K., Ramli, A. S., Mustapha, F., Kosai, N. R., et al. (2022) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15787 · Cited by 46
Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease?
Mazzotti, A., Caletti, M. T., Marchignoli, F., Forlani, G., & Marchesini, G. (2017) · Digestive and Liver Disease · doi:10.1016/j.dld.2016.12.028 · Cited by 46
Fouad, Y. M., Esmat, G., Elwakil, R., Zakaria, S., Yosry, A., Waked, I. A., El-Razky, M., Doss, W. H., El‐Serafy, M., Mostafa, E., et al. (2022) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_357_21 · Cited by 55
Wang, Y., Zhou, Y., Wang, Z., Ni, Y., Prud’homme, G. J., & WANG, Q. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf336 · Cited by 65
Thyroid hormone analogues and derivatives: Actions in fatty liver
Coppola, M. (2014) · World Journal of Hepatology · doi:10.4254/wjh.v6.i3.114 · Cited by 46
Leikin-Frenkel, A. I., Gonen, A., Shaish, A., Goldiner, I., Leikin-Gobbi, D., Konikoff, F. M., Harats, D., & Gilat, T. (2010) · Archives of Medical Research · doi:10.1016/j.arcmed.2010.09.001 · Cited by 50
“Furthermore, the thiaglitazones, the only compounds convincingly shown to reduce liver fat in NAFLD, are known to increase obesity (21,22) and were recently implicated in increasing CVD complications (23).”
Backgroundvan der Veen, J. N., Lingrell, S., Gao, X., Quiroga, A. D., Takawale, A. R., Armstrong, E. A., Yager, J. Y., Kassiri, Z., Lehner, R. S., Vance, D. E., et al. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00243.2015 · Cited by 55
“The controversy is that administration of TZDs to humans is actually beneficial in the treatment of NAFLD (2, 46).”
BackgroundGanguli, S., Deleeuw, P., & Satapathy, S. K. (2019) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s188991 · Cited by 50
Preparing for the NASH Epidemic: A Call to Action
Kanwal, F., Shubrook, J. H., Younossi, Z., Natarajan, Y., Bugianesi, E., Rinella, M. E., Harrison, S. A., Mantzoros, C., Pfotenhauer, K., Klein, S., et al. (2021) · Diabetes Care · doi:10.2337/dci21-0020 · Cited by 45
Self-citationZhang, W., Li, C., Liu, B., Wu, R., Zou, N., Xu, Y.-Z., Yang, Y., Zhang, F., Zhou, H.-M., Wan, K., et al. (2013) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31294-3 · Cited by 45
Liver-targeting drugs and their effect on blood glucose and hepatic lipids
Gastaldelli, A., Stefan, N., & Häring, H. (2021) · Diabetologia · doi:10.1007/s00125-021-05442-2 · Cited by 49
Self-citationMethods for assessing intrahepatic fat content and steatosis
Fabbrini, E., Conte, C., & Magkos, F. (2009) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e32832eb587 · Cited by 45
Treatment regimens for non-alcoholic fatty liver disease
Lam, B. P., & Younossi, Z. M. (2009) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31827-7 · Cited by 51
Birech, Z., Mwangi, P. W., Bukachi, F., & Mandela, K. M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0185130 · Cited by 50
Comparison of fenofibrate and pioglitazone effects on patients with nonalcoholic fatty liver disease
Yaghoubi, M., Jafari, S., Sajedi, B., Gohari, S., Akbarieh, S., Heydari, A. H., & Jameshoorani, M. (2017) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000981 · Cited by 45
Polyphenols and Flavonoids in Controlling Non-Alcoholic Steatohepatitis
Jadeja, R. N., & Devkar, R. V. (2013) · Polyphenols in Human Health and Disease · doi:10.1016/b978-0-12-398456-2.00047-5 · Cited by 52
Nascè, A., Gariani, K., Jornayvaz, F. R., & Szántó, I. (2022) · Antioxidants · doi:10.3390/antiox11061131 · Cited by 56
“Thiazolidinediones, acting as PPARγ activators, showed some improvements in liver steatosis and lobular inflammation but exerted only a minor effect on fibrosis [304,305].”
BackgroundLavynenko, O., Abdul‐Ghani, M., Alatrach, M., Puckett, C., Adams, J., Abdelgani, S., Alkhouri, N., Triplitt, C., Clarke, G. D., Vasquez, J. A., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14650 · Cited by 44
“Participants were drug-naïve, with new-onset (<2 years) T2D according to the American Diabetes Association criteria.(10) Key inclusion criteria were: age 18-75 years; negative glutamic acid decarboxylase antibodies; normal serum chemistries/TSH/T4; stable body weight (±1.”
MethodSelf-citationReview of Treatment Options for Nonalcoholic Fatty Liver Disease
Corrado, R., Torres, D. M., & Harrison, S. A. (2013) · Medical Clinics of North America · doi:10.1016/j.mcna.2013.09.001 · Cited by 46
Self-citationShort-term Effects of Laparoscopic Adjustable Gastric Banding Versus Roux-en-Y Gastric Bypass
Gastaldelli, A., Iaconelli, A., Gaggini, M., Magnone, M. C., Veneziani, A., Rubino, F., & Mingrone, G. (2016) · Diabetes Care · doi:10.2337/dc15-2823 · Cited by 48
Self-citationPortillo‐Sanchez, P., Bril, F., Lomonaco, R., Barb, D., Orsak, B., Bruder, J. M., & Cusi, K. (2019) · Journal of Diabetes · doi:10.1111/1753-0407.12833 · Cited by 43
Self-citationConsenso mexicano de la enfermedad por hígado graso no alcohólico
Bernal-Reyes, R., Castro‐Narro, G., Malé-Velázquez, R., Carmona-Sánchez, R., González-Huezo, M. S., García-Juárez, I., Chávez-Tapia, N. C., Aguilar-Salinas, C., Aiza-Haddad, I., Ballesteros-Amozurrutia, M. A., et al. (2019) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2018.11.007 · Cited by 71
Non-alcoholic fatty liver and chronic kidney disease: Retrospect, introspect, and prospect
Heda, R. P., Yazawa, M., Shi, M. Y., Bhaskaran, M. C., Aloor, F. Z., Thuluvath, P. J., & Satapathy, S. K. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i17.1864 · Cited by 50
Rabøl, R., Boushel, R., Almdal, T., Hansen, C. N., Ploug, T., Haugaard, S. B., Prats, C., Madsbad, S., & Dela, F. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01237.x · Cited by 44
Nonalcoholic Steatohepatitis Drug Development Pipeline: An Update
Chew, N., Ng, C. H., Truong, E., Noureddin, M., & Kowdley, K. V. (2022) · Seminars in Liver Disease · doi:10.1055/a-1877-9656 · Cited by 52
Current Status in the Therapy of Liver Diseases
Uhl, P., Fricker, G., Haberkorn, U., & Mier, W. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15057500 · Cited by 49
“Non-alcoholic fatty liver disease (NAFLD), which is characterized by insulin resistance and necroinflammation with or without centrilobular fibrosis, increases the risk of developing diabetes and metabolic syndrome, resulting in liver cirrhosis and liver-related death [31,32].”
BackgroundHigh-fat and obesogenic diets: current and future strategies to fight obesity and diabetes
Teodoro, J. S., Varela, A. T. I. F., Rolo, A. P., & Palmeira, C. M. (2014) · Genes & Nutrition · doi:10.1007/s12263-014-0406-6 · Cited by 51
Regulation of adiponectin receptor expression in human liver and a hepatocyte cell line
Shimizu, A., Takamura, T., Matsuzawa, N., Nakamura, S., Nabemoto, S., Takeshita, Y., Misu, H., Kurita, S., Sakurai, M., Yokoyama, M., et al. (2007) · Metabolism · doi:10.1016/j.metabol.2007.06.013 · Cited by 49
“A thiazolidinedione controls the abundance of genes relevant for glucose and fatty acid metabolism and ameliorates insulin resistance and liver pathology in both experimental models [32] and patients [33,34] with NASH.”
BackgroundKuś, E., Zabielski, P., Kochan, K., Kuś, K., Jasztal, A., Sitek, B., Proniewski, B., Wójcik, T., Gula, K., Kij, A., et al. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.12.004 · Cited by 44
Review article: the management of paediatric nonalcoholic fatty liver disease
Mitchel, E. B., & Lavine, J. E. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12972 · Cited by 48
Treatment of Non-Alcoholic Fatty Liver Disease
Dyson, J. K., & Day, C. (2014) · Digestive Diseases · doi:10.1159/000360511 · Cited by 55
Laplante, M., Festuccia, W. T., Soucy, G., Blanchard, P.-G., Renaud, A., Berger, J. P., Olivecrona, G., & Deshaies, Y. (2009) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.90552.2008 · Cited by 43
Naturally Occurring Stilbenoid TSG Reverses Non-Alcoholic Fatty Liver Diseases via Gut-Liver Axis
Lin, P., Lu, J., Wang, Y., Gu, W., Yu, J., & Zhao, R. (2015) · PLOS ONE · doi:10.1371/journal.pone.0140346 · Cited by 43
“Drug treatment remains an important part of addressing these issues, which include insulin sensitizers (metformin [13] and thiazolidinediones [14]), vitamin E [15], and statins [16].”
BackgroundAndo, W., Yokomori, H., Tsutsui, N., Yamanouchi, E., Suzuki, Y., Oda, M., Inagaki, Y., Otori, K., & Okazaki, I. (2017) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2017.0030 · Cited by 44
Nonalcoholic fatty liver disease (NAFLD): Diagnosis, pitfalls, and staging
Koch, L. K., & Yeh, M. M. (2018) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2018.09.009 · Cited by 47
Overview of Updated Practice Guidelines for Pediatric Nonalcoholic Fatty Liver Disease.
Shah, J., Okubote, T. C., & Alkhouri, N. (2018) · Europe PMC (PubMed Central) · Cited by 58
Johansson, L., Hockings, P. D., Johnsson, E., Dronamraju, N., Maaske, J., Garcia‐Sanchez, R., & Wilding, J. P. H. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14004 · Cited by 41
Pan, C. S., Weiss, J. J., Fourman, L. T., Buckless, C. G., Branch, K. L., Lee, H., Torriani, M., Bredella, M. A., & Stanley, T. L. (2020) · Clinical Endocrinology · doi:10.1111/cen.14344 · Cited by 46
Preparing for the NASH epidemic: A call to action
Kanwal, F., Shubrook, J. H., Younossi, Z. M., Natarajan, Y., Bugianesi, E., Rinella, M. E., Harrison, S. A., Mantzoros, C. S., Pfotenhauer, K. M., Klein, S., et al. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154822 · Cited by 53
Self-citationGan, S. K., & Watts, G. F. (2008) · Clinical Science · doi:10.1042/cs20070461 · Cited by 48
Efficacy of pioglitazone in familial partial lipodystrophy of the Dunnigan type: a case report
Moreau, F., Boullu-Sanchis, S., Vigouroux, C., Lucescu, C., Lascols, O., Sapin, R., Ruimy, D., Guerci, B., Pinget, M., & Jeandidier, N. (2007) · Diabetes & Metabolism · doi:10.1016/j.diabet.2007.04.005 · Cited by 46
Mirarchi, L., Amodeo, S., Citarrella, R., Licata, A., Soresi, M., & Giannitrapani, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073668 · Cited by 44
“On the other hand, while pioglitazone seems to show a statistically significant improvement compared to placebo, the side effects of its use are substantial, including water retention, weight gain, and cardiovascular risk, thus limiting its use [65].”
BackgroundTherapeutic approaches to non-alcoholic fatty liver disease: past achievements and future challenges
Xiao, J., Guo, R., Fung, M., Liong, E. C., & Tipoe, G. L. (2013) · Hepatobiliary & pancreatic diseases international · doi:10.1016/s1499-3872(13)60021-1 · Cited by 48
Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease
Federico, A., Zulli, C., de Sio, I., Prete, A. D., Dallio, M., Masarone, M., & Loguercio, C. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i45.16841 · Cited by 50
Pediatric Nonalcoholic Fatty Liver Disease: A Comprehensive Review
Lindback, S., Gabbert, C. C., Johnson, B. L., Smorodinsky, E., Sirlin, C. B., Garcia, N. C., Pardee, P. E., Kistler, K. D., & Schwimmer, J. B. (2010) · Advances in Pediatrics · doi:10.1016/j.yapd.2010.08.006 · Cited by 43
“[195,196].”
BackgroundNon-alcoholic fatty liver disease: need for a balanced nutritional source
Veena, J., Anjaneyulu, M., Sidgiddi, S., & Subramaniam, S. (2014) · British Journal Of Nutrition · doi:10.1017/s0007114514002591 · Cited by 47
“Moreover, it appears that the way by which metabolic control is achieved is important in NAFLD: while metformin may be beneficial in NASH and pioglitazone is highly effective((107)), the control of hyperglycaemia by insulin therapy alone has modest benefits on hepatic fat accumulation (K Cusi, unpublished results).”
BackgroundZhang, C., Liao, Y., Li, Q., Chen, M., Zhao, Q., Deng, R., Wu, C., Yang, A., Guo, Z., Wang, D., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066382 · Cited by 46
Mcl-1 Degradation during Hepatocyte Lipoapoptosis
Masuoka, H. C., Mott, J., Bronk, S. F., Werneburg, N. W., Akazawa, Y., Kaufmann, S. H., & Gores, G. J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.039545 · Cited by 42
Katz, M. H. (2010) · Cited by 43
How to measure hepatic insulin resistance?
Choukem, S. P., & Gautier, J. (2008) · Diabetes & Metabolism · doi:10.1016/s1262-3636(08)74602-0 · Cited by 57
“or post-load outcome of ingested glucose [32,33].”
Pharmacological and non-pharmacological treatment of non-alcoholic fatty liver disease
Kaser, S., Ebenbichler, C. F., & Tilg, H. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02327.x · Cited by 46
Role of nonalcoholic fatty liver disease in the development of insulin resistance and diabetes
Grønbæk, H., Thomsen, K. L., Rungby, J., Schmitz, O., & Vilstrup, H. (2008) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2.5.705 · Cited by 52
Pallayová, M., & Taheri, S. (2014) · Clinical Obesity · doi:10.1111/cob.12068 · Cited by 47
Paniagua, J. A., Escandell-Morales, J. M., Gil-Contreras, D., de la Rosa, F. J. B., Romero-Jimenez, M., Gómez-Urbano, A., Sánchez‐López, Á. M., Bellido, E., Poyato, A., Calatayud, B. M., et al. (2014) · Nutrition · doi:10.1016/j.nut.2013.07.017 · Cited by 41
“Additionally, this is important because that PPARG pharmacologic ligands, such as the thiazolidinediones, increase peripheral AT capacity and decreases liver fat deposition, resulting in a healthier insulin action and liver enzymatic profile [46].”
BackgroundThe effect of pioglitazone on weight, lipid profile and liver enzymes in type 2 diabetic patients
Aghamohammadzadeh, N., Niafar, M., Abdollahinia, E. D., Najafipour, F., Gharebaghi, S. M., Adabi, K., Abdolahinia, E. D., & Ahadi, H. (2015) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018815574229 · Cited by 48
“Belfort and colleagues also observed significant reduction in AST and ALT levels following pioglitazone therapy in patients with nonalcoholic steatohepatitis [Belfort et al. 2006].”
BackgroundRegev, A., Palmer, M., Avigan, M. I., Dimick‐Santos, L., Treem, W. R., Marcinak, J. F., Seekins, D., Krishna, G., Anania, F. A., Freston, J. W., et al. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15153 · Cited by 41
“Elevated baseline is defined as ALT ≥1.5× ULN.”
InfluentialBarritt, A. S., Marshman, E., & Noureddin, M. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16794 · Cited by 46
Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives
Clayton‐Chubb, D., Kemp, W. W., Majeed, A., Lubel, J. S., Hodge, A., & Roberts, S. K. (2023) · Nutrients · doi:10.3390/nu15030687 · Cited by 48
“Pioglitazone’s benefits have been seen in both a non-diabetic cohort [235] and a T2DM cohort [234,237].”
BackgroundHepatic Fibrosis and Cirrhosis
Rockey, D. C. (2015) · Wiley eBooks · doi:10.1002/9781118512074.ch105 · Cited by 41
Larrain, S., & Rinella, M. E. (2012) · Clinics in Liver Disease · doi:10.1016/j.cld.2012.05.009 · Cited by 40
Petta, S., Macaluso, F. S., Barcellona, M. R., Cammà, C., Cabibi, D., Marco, V. D., & Craxì, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051165 · Cited by 47
The role of fenofibrate in clinical practice
Zambon, A., & Cusi, K. J. (2007) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2007.053 · Cited by 44
Self-citationMedical and Surgical Treatment Options for Nonalcoholic Steatohepatitis
Corey, K. E., & Rinella, M. E. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4083-8 · Cited by 44
“[41] evaluated pioglitazone 45 mg daily in those with NASH and diabetes mellitus or insulin resistance.”
Ye, L., Cao, Z., Lai, X., Shi, Y., & Zhou, N. (2020) · The Journal of Nutrition · doi:10.1093/jn/nxz303 · Cited by 39
Zhang, Y., Liu, X., Zhang, H., & Wang, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.836455 · Cited by 47
“Although the insulin sensitizer pioglitazone has been proven to enhance metabolism and liver histology among NAFLD patients, it has limitations in clinical use due to significant adverse events including weight gain, lower extremity edema, and heart failure (12, 13).”
BackgroundKauffman, R. P., Baker, T. E., Baker, V., Kauffman, M. M., & Castracane, V. D. (2010) · Gynecological Endocrinology · doi:10.3109/09513590903184084 · Cited by 40
Yoneda, M., Kobayashi, T., Honda, Y., Ogawa, Y., Kessoku, T., Imajo, K., Nogami, A., Taguri, M., Kirikoshi, H., Saito, S., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1993 · Cited by 44
“In a large randomized controlled trial of 24 weeks of treatment, pioglitazone was found to reduce serum liver enzymes, histological hepatic steatosis, hepatocyte ballooning, and inflammation.[27] At 3year long- term follow- up, 58% of patients maintained improvement in NASH histologically, and 51% had resolution of NA…”
BackgroundJiang, Y., Wu, L., Zhu, X., Bian, H., Gao, X., & Xia, M. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02092-2 · Cited by 52
“As summarized in Table 1, clinical trials of pioglitazone showed significant improvement in IR, liver steatosis and inflammation compared with placebo [54, 55].”
BackgroundZisis, M., Chondrogianni, M. E., Ανδρουτσάκος, Θ., Rantos, I., Oikonomou, E. K., Chatzigeorgiou, A., & Kassi, E. N. (2025) · Biomolecules · doi:10.3390/biom15030324 · Cited by 48
“…randomized clinical trial by Takeshita et al. demonstrated that treatment with 10 mg of ezetimibe for 6 months significantly reduced serum total cholesterol, fibrosis staging, and ballooning score, with no statistically significant effect on serum aminotransferase levels and hepatic steatosis.”
Pioglitazone in the Treatment of Type 2 Diabetes: Safety and Efficacy Review
Desouza, C. V., & Shivaswamy, V. (2010) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.4137/cmed.s5372 · Cited by 48
Kurikawa, N., Takagi, T., Wakimoto, S., Uto, Y., Terashima, H., Kono, K., Ogata, T., & Ohsumi, J. (2013) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b12-00702 · Cited by 39
Steatosis and Steatohepatitis: Complex Disorders
Bettermann, K., Hohensee, T., & Haybaeck, J. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15069924 · Cited by 48
“Another double-blind study recognized a significant improved steatosis, ballooning and inflammation in 73% of the NASH patients [110].”
BackgroundManagement of Non-alcoholic Fatty Liver Disease and Steatohepatitis
Le, T., & Loomba, R. S. (2012) · Journal of Clinical and Experimental Hepatology · doi:10.1016/s0973-6883(12)60104-2 · Cited by 45
Thiazolidinediones for Nonalcoholic Steatohepatitis — Promising but Not Ready for Prime Time
McCullough, A. J. (2006) · New England Journal of Medicine · doi:10.1056/nejme068232 · Cited by 39
Thirunavukkarasu, K., Rajkumar, P. R., Selvaraj, S., Gunasekaran, S., & Kumaresan, S. (2018) · Chemical Data Collections · doi:10.1016/j.cdc.2018.09.006 · Cited by 38
Somi, M. H., Fatahi, E., Panahi, J., Havasian, M. R., & Judaki, A. (2014) · Bioinformation · doi:10.6026/97320630010575 · Cited by 39
Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis
Ratziu, V., Ghabril, M., Romero-Gomez, M., & Svegliati-Baroni, G. (2019) · Transplantation · doi:10.1097/tp.0000000000002483 · Cited by 38
Nuclear receptors and transcriptional regulation in non-alcoholic fatty liver disease
Xiao, Y., Kim, M., & Lazar, M. A. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101119 · Cited by 43
Metadata
- Authors
- Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., Berria, R., Ma, J. Z., Dwivedi, S., Havranek, R., Fincke, C., DeFronzo, R., Bannayan, G. A., Schenker, S., & Cusi, K.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Brooke Army Medical Center (US)
- South Texas Veterans Health Care System (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-11-30
- Volume
- 355
- Issue
- 22
- Pages
- 2297-2307
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2103156933
- Cited by
- 1,827
- References
- 38
- Citations by year
- 2026: 44 · 2025: 73 · 2024: 83 · 2023: 78 · 2022: 84 · 2021: 93 · 2020: 73 · 2019: 74 · 2018: 70 · 2017: 93 · 2016: 98 · 2015: 106 · 2014: 92 · 2013: 87 · 2012: 85
- FWCI
- 91.90
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Funders
- National Center for Research Resources (M01RR01346, M01RR001346)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- alcoholic steatohepatitis, thiazolidinediones, insulin resistance, hypocaloric diet, hepatic steatosis, hepatic insulin sensitivity, necroinflammation, liver fibrosis, glucose tolerance, type 2 diabetes, impaired glucose tolerance, hepatic aminotransferases, drug safety, adverse effects
- MeSH terms
- Pioglitazone, Blood Glucose, Combined Modality Therapy, Diabetes Mellitus, Type 2, Double-Blind Method, Fatty Liver, Female, Hepatitis, Humans, Hypoglycemic Agents, Insulin, Insulin Resistance, Liver, Liver Cirrhosis, Male, Middle Aged, Necrosis, Glucose Intolerance, Caloric Restriction, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.